ATP citrate lyase (ACL) inhibitor (IC50 = 0.13 μM for human recombinant ACL); blocks lipid synthesis (IC50 = 8 μM in HepG2 cells). Displays no cytotoxicity up to a concentration of 50 μM. Lowers plasma glucose and triglycerides in a mouse model of hyperlipidemia. Orally bioavailable.
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 424.3. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.36 mL||11.78 mL||23.57 mL|
|5 mM||0.47 mL||2.36 mL||4.71 mL|
|10 mM||0.24 mL||1.18 mL||2.36 mL|
|50 mM||0.05 mL||0.24 mL||0.47 mL|
The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.
References are publications that support the products' biological activity.
Li et al (2007) 2-hydroxy-N-arylbenzenesulfonamides as ATP-citrate lyase inhibitors. Bioorg.Med.Chem.Lett. 17 3208 PMID: 17383874
Ma et al (2009) A novel direct homogeneous assay for ATP citrate lyase. J.Lipid Res. 50 2131 PMID: 19286649
If you know of a relevant reference for BMS 303141, please let us know.
View Related Products by Product Action
Keywords: BMS303141 ATP citrate lyases inhibits inhibitors plasma glucose triglycerides orally bioavailable synthases transferases ACLY ATP Citrate Lyase
Citations for BMS 303141
Citations are publications that use Tocris products.
Currently there are no citations for BMS 303141. Do you know of a great paper that uses BMS 303141 from Tocris? If so please let us know.